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An in situ crosslinkable, biodegradable, methacrylate-endcapped poly(D,L-lactide-co-e-caprolactone) in which
crosslinkage is achieved by photoinitiators was developed for bone tissue regeneration. Different combinations
of the polymer with bone marrow–derived mesenchymal stem cells (BMSCs) and a-tricalcium phosphate (a-TCP)
were tested in a unicortical tibial defect model in eight goats. The polymers were randomly applied in one of three
defects (6.0 mm diameter) using a fourth unfilled defect as control. Biocompatibility and bone-healing charac-
teristics were evaluated by serial radiographies, histology, histomorphometry, and immunohistochemistry. The
results demonstrated cell survival and proliferation in the polymer-substituted bone defects. The addition of
a-TCP was associated with less expansion and growth of the BMSCs than other polymer composites.
Introduction
Large bone defects in humans and animals generally donot heal spontaneously and require, in most cases, a spe-
cific surgical intervention for the reconstruction of the defect.
One of the possibilities is the use of an autologous trabecular
graft. The inherent drawback of an autologous graft, how-
ever, is that the grafts have to be harvested from another place
in the body, resulting in donor-site morbidity.1 A possible
alternative is the use of allogenic bone collected from a donor
of the same species. These grafts were proven to have a
lower osteogenic capacity, a higher resorption rate, a larger
immunogenic response, and less extensive revascularization
than autologous grafts. Further, there are justified concerns
about possible viral contamination of the graft material, in-
cluding transmission of live virus to the recipient.2
Bone regeneration using tissue engineering techniques
has emerged as an alternative approach in the treatment of
malfunctioning or depleted bone. In this approach, a bio-
material scaffold can be implanted in the bone defect. This
scaffold serves as an adhesive substrate for seeded cells and
assures a sufficient physical support to guide the formation
of the new bone-related extracellular matrix (ECM). The use
of autologous cell sources has received widespread attention
because of the potential benefits in the tissue engineering
process.3–5
The design criteria for polymeric scaffolds for bone tissue
support include a high porosity, structural integrity, and
degradability at a rate commensurate with the production of
new ECM by cells seeded on the scaffold. A highly porous
scaffold is desirable to allow uniform cell migration through-
out the material and to optimize transport to and from
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implanted cells. Pore size and interconnectivity play a major
role in tissue ingrowth, creating an internal surface area avail-
able for cell attachment, spreading, and expansion. The
mechanical properties of the scaffold are also of major im-
portance, especially with respect to hard tissues such as
bone, to transmit mechanical force and manage mineraliza-
tion requirements.6
We previously reported that the in situ crosslinkable
methacrylate-endcapped porous bone scaffold composed
of D,L-lactide, e-caprolactone, 1,6-hexanediol, and poly
(orthoesters) could be used as a substrate for bone tissue en-
gineering.7 This polymer showed excellent biocompatibility
and moderate osteoconductive properties in vivo. The addi-
tion of a-tricalcium phosphate (a-TCP) increased the latter
characteristics.7 In other parallel experimental work, mouse
embryonic stem cells were cultivated on commercially avail-
able biodegradable macroporous microcarriers, and osteo-
genic differentiation was initiated in an adapted medium for
a period of 2 weeks. Encapsulation of the cell-loaded micro-
carriers in the experimental scaffold, using either triacetin or
hydroxyethylmethacrylate (HEMA), as solvent and with or
without gelatine, as porogen, resulted in a homogeneous
distribution of the microcarriers in the polymer. However,
viability of the cells was estimated by transmission electronic
microscopy to be optimal when gelatine was omitted, and
triacetin was added instead of HEMA.8
The objective of the present study was to evaluate the
effect of mesenchymal stem cells loaded on microcarriers in
combination with the crosslinkable methacrylate-endcapped
porous polymer scaffold including a-TCP on bone regener-
ation in a unicortical tibial defect experimental design in a
goat model. We firstly hypothesized that the implanted cells
would easily survive and proliferate, and would demonstrate
bone-forming characteristics inside the polymer scaffold. We
secondly anticipated an improvement in bone healing char-
acteristics of the treated cortical defects compared to earlier
reported results concerning a comparable experiment with-
out the use of stem cells.7
Materials and Methods
The study was approved by the Ethics Committee of
the Faculty of Veterinary Medicine, Ghent University (EC
2006=097). Eight adult female goats with a mean age of
46.3 22.9 months and a mean body weight of 54.1 7.5 kg
were used. The goats were housed in groups (groups of four
in boxes of 16 m2) and had free access to food and water. All
surgical procedures were performed under general anesthe-
sia respecting all aspects of the well-being of the animals
(including starvation before surgery, as well as antibiotics
and analgesics before, during, and after surgery).7
Isolation and culture of bone marrow–derived cells
Bone marrow (BM) was aspirated by a Jamshidi needle (11
gauge, 10 cm; DMS, Hampshire, United Kingdom) under
sterile conditions from the iliac crest of the anesthetized
goats. The BM was collected in a 10 mL lithium heparin tube
(Venoject, Leuven, Belgium) in which 1 mL of ACD-A anti-
coagulant (Anticoagulant Citrate Dextrose Solution Formula
A; Baxter, Brussels, Belgium) was added. The needle was
abundantly flushed with ACD-A anticoagulant and lithium
heparin before the aspiration of the BM. After removal of
blood clots, the BM was thoroughly washed with Minimum
Essential Medium (MEM)-a medium containing 10 vol%
fetal bovine serum (FBS), 0.5 vol% penicillin–streptomycin,
and 1 vol% Funigizone Amphotericin B (Invitrogen, Mer-
elbeke, Belgium), and centrifuged (10 min, 1000 rpm). The
cell pellet was resuspended in osteogenic differentiation
medium, that is, MEM-a medium supplemented with 10
vol% FBS, 0.5 vol% penicillin–streptomycin, 1 vol% Fungi-
zone Amphotericin B, 100mM L-ascorbic acid 2-phosphate
(Sigma-Aldrich NV=SA, Bornem, Belgium), and 10 nM
dexamethasone (Sigma-Aldrich NV=SA), and seeded in five
T75 tissue culture dishes. The culture dishes were placed in a
humidified incubator (378C, 5% CO2=95% air), and the me-
dium was renewed after 2 days, leading to the removal of the
nonadherent cells (mainly hematopoietic cells). Stromal cells
were kept in culture for 2 weeks (renewal of the medium
twice a week) until they reached confluence. Afterward
trypsinized, the cells were brought in suspension, stained
with trypan blue, and counted in a Bu¨rcker cell chamber.
CultiSpher-S microcarriers (diameter 130–380 mm) (Percell
Biolytica AB, A˚storp, Sweden) were prepared and sterilized
according to the manufacturer’s instruction. About 0.09 g
hydrated carriers were divided over 5 wells of a 12-well
suspension plate in osteogenic medium. Approximately
400,000 cells were added to each well, depending on the
amount of harvested cells. Cells were allowed to adhere
under static conditions for 48 h. Afterward, the cell–carrier
constructs were carefully transferred to a dynamic culture
system (stirring speed 55 rpm) as has been described by
Declercq et al.9 The constructs were cultured for an addi-
tional 2–3 weeks in osteogenic differentiation medium, with
the addition of b-glycerophosphate after 1-week colonization
at 378C (5% CO2). Before implantation, cell colonization on
the carriers was evaluated by 3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
salt (MTS) analysis (100mL MTS solution added to 100mL
CultiSpher carriers in 500mL phenol-red–free medium). After
4-h incubation in the dark at 378C, the reduction of the tet-
razolium salt into formazan in living cells was determined
spectrophotometrically by measuring the absorbance of the
colored formazan at a wavelength of 480 nm. The cell-loaded
constructs were mixed with the polymer and implanted in
the tibial defects.
Preparation of scaffolds
The synthesis and characterization of the methacrylate-
endcapped polymers (D,L-lactide-co-caprolactone) have
been described in depth earlier.7–9 Composition of the scaf-
folds was selected based on the results previously re-
ported.8,9 No extra porogen was included in the composition
of the scaffolds. Preceding experiments showed that porosity
could be induced by the leaching of the plastizer and as a
result of the degradation of the polyester and the CultiSpher
microcarrier particles. Further, during the mixing of the
viscous crosslinkable polyester and the cell-seeded micro-
carriers, air bubbles were trapped and contributed as mac-
roporous pockets. In vitro experiments with cells grown on
microcarriers and immobilized in the crosslinkable polyester
proved to maintain an acceptable viability.
Three different preparations of the scaffold were used
in the present study. Composite no. 1 consisted of pure
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methacrylate-endcapped polymer with a triacetin solution
containing the photoinitiators as plasticizers. In composite
no. 2, this mixture was supplemented with microcarriers
loaded with autologous mesenchymal stem cells differenti-
ated in the osteogenic lineage. In composite no. 3, 30% w=w
a-TCP was further added to the polymer–triacetin–microcarrier
mixture.
All polymers were sterilized by ethylene oxide for 12 h at
378C and subsequently aerated for 48 h. The cell-loaded
CultiSpher-S carriers were thoroughly rinsed with physio-
logical solution and shortly dehydrated by pipetting the
constructs on filter paper. Two hundred and fifty microli-
ters of these carriers were added to the catalyst=triacetin=
polymer=(a-TCP) paste and carefully mixed.
Surgical procedure
The surgery was performed as described earlier.7 Briefly,
four noncritical-sized defects (6.0 mm diameter) were drilled
in the medial diaphyseal cortex of each tibia using a trephine
burr (3I; Implant Innovations, Copenhagen, Denmark). In
each leg, the three composites were randomly assigned to a
hole, whereas the fourth hole was left empty to serve as a
control. Each composite was first placed on the borders and
bottom of the defect, and photopolymerized for 40 s
(500 mW=cm2 blue light, Visible Light Curing UnitTM; 3M
Unitek, Diegem, Belgium). Afterward, the remaining defect
was further filled with a second layer of additional polymer
before the standard wound closure.
During the study period, goats were daily evaluated for
healing of the surgical site and development of complications
related to the surgical intervention.
At, respectively, 2, 4, 8, and 12 weeks after surgery, two
goats were euthanized and tibial defects were harvested for
histological and immunohistochemical analysis of bone
healing.
Clinical and radiographic follow-up
During the complete study period, goats were daily
clinically evaluated for healing of the surgical site and de-
velopment of possible complications related to the surgical
intervention.
Immediately after surgery, standardized craniocaudal and
mediolateral digital radiographs (Digivex 40 15 kW high-
frequency generator; Medex Loncin S.A., Loncin, Belgium) of
each tibia were taken. At 2 weeks’ interval, healing of the
tibial defects was radiographically evaluated in each goat
until the time of euthanasia, when further histological and
immunohistochemical analysis of the bone defects was per-
formed.
All radiographs were blindly evaluated for defect radio-
graphic density, periosteal reaction, and soft tissue reaction
using the criteria described by Dorea et al.10 Gray-scale
densities at the level of the bone defects were further objec-
tively evaluated using a standard imaging software packet
(Image J 1.34S; National Institutes of Health, Bethesda,
Maryland).
Histological and immunohistochemical analysis
After euthanasia, the different bone defect sites were
harvested from the tibias. Because it was one of the aims to
perform a von Kossa staining on the histological sections,
undemineralized samples were embedded in destabilized
Technovit 9100 New (Heraeus Kulzer, Wehrheim, Germany)
as described earlier.7 Four-micrometer sections were cut
with a heavy duty microtome (SM2500; Leica Microsystems,
Wetzlar, Germany), stretched with 70% ethanol on a slide,
and dried for 12 h at 608C.
The sections were stained with hematoxylin and eosin
(H&E), von Kossa, and Toluidine blue stain. All samples
were qualitatively evaluated using a standard light micro-
scope by the same investigator blinded to treatment. Eva-
luation criteria included the tissue type, presence of residual
graft material within the defect, the quality of bone healing,
and the presence of inflammatory reaction.
Histomorphometric analysis was performed with a 2
magnification (Olympus BX61 Microscope; Olympus Soft
Imaging Solutions GmbH, Mu¨nster, Germany) on the von
Kossa–stained sections using a specific software program
(Analysis 5.0; Olympus Soft Imaging Solutions GMbH). The
surface area of von Kossa–positive (black-brown coloration
representing calcified tissue), von Kossa–negative (violet
coloration representing connective tissue), and colorless (re-
presenting polymer and artifacts) stained materials were mea-
sured and expressed as a percentage of the total defect area.
All sections were stained immunohistochemically for
cluster of differentiation 3 (CD3) (lymphocytes), MAC387
(macrophages), vimentin (mesenchymal tissue), and osteo-
calcin,11 and evaluated for the presence and localization of
positive staining. Before immunohistochemical staining,
sections were deacrylized. Antigen retrieval was performed
using proteinase K (Dako, Heverlee, Belgium). The sections
were rinsed with distilled water and phosphate-buffered
saline (PBS). Endogenous peroxidase was quenched by in-
cubating the sections in a 3% hydrogen peroxide solution in
methanol. This was followed by rinsing in distilled water
and PBS. The sections were preincubated in bovine serum
albumin and rinsed with PBS. Consequently, immunohisto-
chemical staining was performed using the primary anti-
body. The sections were rinsed with PBS and incubated with
biotinylated goat anti-mouse for the monoclonal primary
antibodies and biotinylated goat anti-rabbit for the poly-
clonal antibodies. Afterward, the sections were rinsed and
incubated with avidin-biotin complex-horseradish perox-
idase (Dako). The samples were rinsed with PBS and incu-
bated in 3,30-diaminobenzedine (Sigma, Bornem, Belgium)
and finally rinsed with distilled water. Counterstaining was
done by immersing the sections in hematoxylin, tap water,
and distilled water. Finally, the sections were dehydrated
and covered. The described protocol was used for all im-
munostainings except for CD3, where the PBS was changed
for tris-buffered saline.11
Statistical analysis
Relationships between the age of the goats, and the vol-
ume of BM and retrieved cells after culturing were studied
by the Pearson’s correlation coefficient.
The radiographic scores for defect radiographic density,
periosteal reaction, and soft tissue reaction were compared
between the three composites, and the control defect by the
Friedman test with tibia and time as block factor at the 5%
global significance level. The three composites and the control
PRELIMINARY STUDY IN DEVELOPMENT OF BONE SCAFFOLD 1503
defect were pair-wise compared by the stratified Wilcoxon
rank sum test using Bonferroni’s multiple comparisons ad-
justment technique. The digital radiographic density assess-
ments were analyzed by a mixed model with tibia as random
effect and composite, time, position, and the interaction be-
tween composite and time as categorical fixed effects at the
5% global significance level.
Histological bone healing assessments were analyzed by
a mixed model with tibia as random effect and compos-
ite, time, and the interaction between composite and time
as categorical fixed effects at the 5% global significance level.
Pair-wise comparisons in the mixed model were based on
Bonferroni’s multiple comparisons adjustment technique.
Results
All of the graft materials were easily implanted into the
tibial defects and were considered to be stable before wound
closure. None of the goats expressed signs of pain or lame-
ness during the study period. Except for transient, discrete
subcutaneous fluid accumulation at the surgical incision in
the left tibia of three animals 2– 4 weeks after surgery, no
other clinically visible adverse reactions were observed.
These minor seromas were successfully treated in all cases by
sterile puncture and pressure bandages for several days.
Isolation and culture of BM-derived cells
The quantitative values of each BM sample and their
characteristics after culturing and seeding on microcarriers
are represented in Table 1. A mean volume of 11.5 5.1 mL
BM could be aspirated. A mean amount of 4.07 2.4106
BM-derived mesenchymal stem cells (BMSCs) was retrieved
after a culture period of 14 days. On average 1.70
0.3106 cells were loaded on 0.09 g microcarriers for a mean
period of 20.0 3.7 days before implantation. The result of
the BM punctures differed largely between the goats. There
was no significant correlation between the age of the goats
and the volume of retrieved BM (Pearson’s correlation co-
efficient, 0.198; p¼ 0.639). No significant correlation could be
FIG. 1. Box plots re-
presenting the differences
in assessments for radio-
graphic density (dens),
distribution of the perios-
teal reaction and callus
formation (dis), size of the
periosteal reaction and cal-
lus formation (peri), and
the soft tissue reaction
(soft) between the several
defects on the radio-
graphies. X-axis: differ-
ences between defects with
0 indicating control defect,
and 1, 2, and 3 indicating
composite nos. 1, 2, and 3,
respectively. Y-axis: result
of differences.
Table 1. Quantitative Values of the Bone Marrow Harvested from the Iliac Arch in Eight Goats
Goat 1 Goat 2 Goat 3 Goat 4 Goat 5 Goat 6 Goat 7 Goat 8
Age (months) 34 91 32 35 35 21 60 62
Vol BM (mL) 6 11 8 9 8 17 21 12
# Cells 14 d culture 8.28106 3.66106 2.00106 2.75106 1.48106 6.00106 2.36106 6.00106
# Cells on microcarriers 6.00106 3.66106 2.00106 2.75106 1.48106 6.00106 2.36106 6.00106
# Carriers (g) 0.27 0.18 0.126 0.18 0.09 0.27 0.144 0.27
# Cells=0.09 g carrier 2.00106 1.83106 1.42106 1.38106 1.48106 2.00106 1.48106 2.00106
Period on carriers (days) 17 19 25 25 22 16 16 20
Age (months): age of each goat in months at the day of bone marrow puncture. Vol BM (in mL): volume bone marrow after removal of
potential blood clots. # Cells 14 d culture: total amount of cells after 14 days of culture. # Cells on microcarriers: quantity of cells used for
seeding on microcarriers. # Carriers (in g): quantity of carriers. # Cells=0.09 g carrier: quantity of cells=0.09 g carrier. Period on carriers (in
days): period that cells were seeded on carriers in osteogenic differentiation medium before surgical implantation.
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demonstrated between the volume of BM and the number of
cells cultivated after 14 days (Pearson’s correlation coeffi-
cient, 0.093; p¼ 0.827) or between the age of the goats and
the amount of cells after 14 days of culture (Pearson’s cor-
relation coefficient, 0.099; p¼ 0.816).
Radiographic follow-up
A significant difference between the composite-treated
and the control defects was found for the distribution of
the periosteal reaction and callus formation over time ( p¼
0.0218), without significant pair-wise comparisons (Fig. 1).
The size of the periosteal reaction and callus formation around
each defect differed significantly between the composites
( p¼ 0.0215), with significant pair-wise comparisons between
composite nos. 1 and 2 ( p¼ 0.004). Composite no. 2 scored
significantly higher than composite no. 1 concerning the size
of the periosteal reaction and callus formation around each
defect (Fig. 1). No significant differences were found with
respect to the radiographic density of each defect over time
and the soft tissue reaction (Fig. 1). This was in accordance
with digitally measured gray-scale levels that revealed no
differences between the defects ( p¼ 0.81) and between the
time periods ( p¼ 0.39). The mean calculated gray-scale values
for the complete study period of the control defect and the
defects containing composite nos. 1, 2, and 3 were 73.8 2.3,
75.8 2.1, 74.4 2.2, and 77.7 2.2, respectively.
Histological evaluation
New bone formation was mostly pronounced in the con-
trol defects, originating at the intact cortex surrounding the
defects and causing complete healing of the defect from 8
weeks after surgery (Fig. 2A). Control defects were filled
with mesenchymal tissue at the center until complete
bridging by bone tissue was achieved. Complete healing
was not observed in the defects filled with the different
FIG. 2. Photomicrographs of tibial defects 8 weeks post-
surgery in a goat (magnification 2, von Kossa staining). (A)
The control defect is completely filled with bone. (B) Defect
filled with composite no. 1. (C) Defect filled with composite
no. 2: the composite is surrounded by a capsule of fibrous
tissue; new bone formation is present around the fibrous
capsule; several centers of tissue are present in the compos-
ite. (D) Defect filled with composite no. 3: several centers of
tissue are present in the composite; the composite is sur-
rounded by a capsule of fibrous tissue. Color images avail-
able online at www.liebertonline.com=ten.
FIG. 3. Photomicrograph of a tibial defect treated with
composite no. 2, 8 weeks after surgery (magnification 20,
H&E staining). Several centers of tissue consisting of micro-
carriers (1), colonized and overgrowth by extracellular ma-
trix, and viable cells (2) are present in the polymer (3). Color
images available online at www.liebertonline.com=ten.
FIG. 4. Photomicrograph of a tibial defect treated with
composite no. 3, 8 weeks after surgery (magnification 20,
H&E staining). Several centers of tissue consisting of micro-
carriers (1) colonized and overgrowth by extracellular matrix
and viable cells (2) are present in the polymer. The polymer
(3) contains diffusely spread granular material (4). Color
images available online at www.liebertonline.com=ten.
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composites during the study period. At 8 and 12 weeks
postsurgery, composite-filled defects were characterized by
the presence of fibrous tissue surrounding the centrally lo-
cated polymer. New bone formation was present in the pe-
riphery of the defects. Polymer degradation was limited over
time. Defects filled with composite nos. 2 and 3 were seen to
contain several cellular tissue islands (Fig. 2C, D) consisting
of microcarriers, connective tissue, and viable cells (Figs. 3
and 4). However, the volume of tissue surrounding the car-
riers in composite no. 3 was considered smaller than in
polymer no. 2. Further, several nuclei incorporated into
composite no. 3 appeared pyknotic. This composite con-
tained also diffusely spread granular material that stained
von Kossa positive and was subsequently identified as a-
TCP (Figs. 4 and 5). In 8 out of 64 tibial defects, clusters of
high concentrations of cells were visible around the com-
posite material.
Histomorphometry
The von Kossa–positive surface area was significantly
influenced by the type of material ( p< 0.0001), time
( p< 0.0001), and the material–time interaction ( p¼ 0.0208).
Control defects contained significantly more von Kossa–
positive material (mean 26.1 6.0%) than composite nos. 1
( p¼ 0.0025), 2 ( p¼ 0.0001), and 3 ( p¼ 0.0015) (mean values
of 10.9 3.4%, 7.3 2.2%, and 10.2 2.4%, respectively) (Fig.
6). No differences were found for this parameter between the
three composites. The percentage of von Kossa–positive
staining increased significantly over time (Fig. 7).
The percentages of von Kossa–negative surface areas were
significantly influenced by the type of material ( p¼ 0.0093),
time ( p¼ 0.0031), and their interaction ( p¼ 0.0116). Control
defects (41.8 7.0%) contained significantly ( p¼ 0.035) more
von Kossa–negative material than defects filled with com-
posite no. 1 (24.1 4.5%). The other composites did not differ
significantly (mean of composite nos. 2 and 3: 29.9 5.1 and
36.1 4.5%, respectively) (Fig. 6). The percentage of von
Kossa–negative staining decreased significantly over time
(Fig. 8).
The percentages of surface area containing colorless ma-
terial were significantly ( p< 0.0001) influenced by the type
of material, but not by time ( p¼ 0.1479) and their interac-
tion ( p¼ 0.4501). Control defects contained significantly less
colorless material (mean 32.1 5.2%) than composite nos. 1
( p¼ 0.0001), 2 ( p¼ 0.0004), and 3 ( p¼ 0.0146) (mean values
of 64.9 6.0%, 62.4 5.7%, and 53.6 5.1%, respectively).
No differences were found between the three composites
(Fig. 9).
FIG. 5. Photomicrograph of a tibial defect treated with
composite no. 3, 12 weeks after surgery (magnification 2, von
Kossa staining). Several centers of tissue (1) are present in the
composite. The composite is surrounded by a capsule of fi-
brous tissue. Several dots of von Kossa–positive tissue are
present in the composite material (2), whereby newly formed
trabecular bone (3) and a mature tibial cortex (4) can be no-
ticed. Color images available online at www.liebertonline
.com=ten.
FIG. 6. Mean percentage (þ standard error of the mean)
of each tibial defect for von Kossa–positive, von Kossa–
negative, and polymer and=or empty space.
FIG. 7. Mean percentage ( standard error of the mean) of
von Kossa–positive material of the tibial defects filled with
different composites in eight goats at 2, 4, 8, and 12 weeks
postsurgery.
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Immunohistochemistry
The CD3 activity examined by immunohistochemical
analysis was negative in all samples except in three samples
from one single goat with a few CD3-positive staining cells
diffusely spread around the implanted composite. Bone tis-
sue and granular material in defects filled with composite no.
3 stained metachromatically.
Immunohistochemical staining for MAC387 (macro-
phages) revealed no positive cells or tissue in the defects at
any time. Bone tissue and the granular material in composite
no. 3 stained metachromatically.
Intensive positive staining for vimentin (mesenchymal
tissue) was observed in the tissue concentrations in composite
nos. 2 and 3, the connective tissue surrounding the com-
posites, and the fibrous tissue inside the cortical bone tissue
(Figs. 10 and 11). Bone tissue and the granular material in
composite no. 3 stained metachromatically.
Immunohistochemical staining for osteocalcin revealed a
slightly positive staining of tissues in and around the micro-
carriers in composite nos. 2 and 3, the connective tissue
surrounding the different composites, and the tissue inside
the newly formed trabecular bone (Figs. 12 and 13).
Discussion
In the present study, the biological behavior of porous
bone scaffolds prepared from methacrylate-endcapped
poly(D,L-lactide-co-e-caprolactone) mixed with BMSCs was
studied in a tibial cortical defect goat model. Critical-sized
defects were not used for this study to facilitate the surgical
procedures during these initial basic steps in the study. They
should, however, be a logical sequel for further experiments.
Although BMSCs survived and showed signs of new bone
formation as stated in the first part of the research hypoth-
esis, bone healing was still in its initial stages in the poly-
mer composites at the end of the study period compared to
control defects where complete healing was present.
Bone tissue engineering has been shown to be an effective
approach for bone regeneration, and BMSCs have proved to
be a major cell source during the bone engineering process.
The osteogenic potential of BMSCs has been demonstrated
extensively both in vitro and in vivo, and many studies have
succeeded in repairing bone defects using BMSCs in different
animal models.12–21 Not only can osteogenically induced
BMSCs provide a source for new bone formation, but the
FIG. 9. Mean percentage ( standard error of the mean) of
colorless material of the tibial defects filled with different
composites in eight goats at 2, 4, 8, and 12 weeks post-
surgery.
FIG. 10. Photomicrograph of a tibial defect treated with
composite no. 2, which stained immunohistochemically for
vimentin 12 weeks after surgery. The capsule of tissue
around the polymer and the tissue centers in the polymer are
positively stained (magnification10). 1, Newly formed bone
(metachromatic staining); 2, capsule of tissue around com-
posite (vimentin positive); 3, microcarrier; 4, tissue and cells
around the microcarrier (vimentin positive); 5, polymer.
Color images available online at www.liebertonline.com=ten.
FIG. 8. Mean percentage ( standard error of the mean) of
von Kossa–negative material of the tibial defects filled with
different composites in eight goats at 2, 4, 8, and 12 weeks
postsurgery.
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transformed cells can also secrete important growth factors
regulating further bone healing.
The present study found no age-related influence on the
number of cultured BMSCs derived from BM punctures in
goats. Kotobuki et al. demonstrated that BMSCs could even
proliferate from aged marrow cells (viability greater than
90%).22 This might suggest that not only young but also geri-
atric patients might be treated with autologous BMSCs or os-
teoblasts derived from BM. Bone reconstruction procedures
are frequently performed in the older individuals, for example,
in oral surgery, to allow stable placement of dental implants
in an augmented bone area.23 Also bone reconstruction after
tumor resection is challenging in the elderly patient.24
Photopolymerizing materials used for bone reconstruction
have promising characteristics: these products can be in-
jected into a bone defect in moldable form and solidified
in situ by exposure to a specific light source, maintaining the
form and shape of the implant.25–31 In the present study,
photopolymerizable scaffolds based on D,L-lactide and e-
caprolactone to encapsulate BMSC-loaded microcarriers
were used in an experimental model for bone regeneration.
Declercq et al. demonstrated in a previous in vitro study that
the encapsulated cells did not show pyknotic nuclei, pointing
out that the photopolymerization and handling of the vis-
cous polymer=microcarrier paste were not detrimental for
the survival of the cells.9 The present study confirmed these
results in an in vivo setting and demonstrated the implanted
cells’ ability to proliferate and produce a calcified matrix
(osteocalcin positive) inside the polymer as cell proliferation
and matrix production were absent in the polymer com-
posite without BMSCs.
Although radiographic evaluation did not reveal major
differences between the control defects and the three different
composites, the control defects had the tendency to become
more dense 6 weeks after surgery than defects filled with
composites. However, the lowest overall mean gray-scale
values were observed in the control defect followed by com-
FIG. 12. Photomicrograph of a center of tissue in tibial
defect treated with composite no. 2, which stained
immunohistochemically for osteocalcin 12 weeks after sur-
gery. There is a slightly positive staining of the tissue, and
the nuclei are staining negative (magnification 40). 1, Mi-
crocarrier; 2, tissue and cells around the microcarrier (slightly
positive); 3, polymer. Color images available online at
www.liebertonline.com=ten.
FIG. 13. Photomicrograph of a tibial defect treated with
composite no. 3, which stained immunohistochemically for
osteocalcin 8 weeks after surgery. There is a slightly positive
staining of the tissue around the microcarriers, the capsule
around the polymer, and the tissue between the newly
formed metachromatically stained trabecular bone. The nu-
clei are staining negative (magnification20). 1, Microcarrier;
2, tissue and cells around the microcarrier (slightly osteo-
calcin positive); 3, polymer; 4, granular material in polymer
(metachromatic staining); 5, capsule of tissue around com-
posite (slightly osteocalcin positive); 6, newly formed bone
(metachromatic staining). Color images available online at
www.liebertonline.com=ten.
FIG. 11. Photomicrograph of a tibial defect treated with
composite no. 3, which stained immunohistochemically for
vimentin 8 weeks after surgery. The tissue between the newly
formed metachromatic staining bone, the capsule of tissue
around the polymer, and the tissue centers in the polymer are
positively stained (magnification10). 1, Microcarrier; 2, tis-
sue and cells around the microcarrier (vimentin positive); 3,
capsule of tissue around composite (vimentin positive); 4,
newly formed bone (metachromatic staining); 5, polymer; 6,
granular material in polymer (metachromatic staining). Color
images available online at www.liebertonline.com=ten.
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posite nos. 2, 1, and 3, respectively (not significantly different).
This finding is in contrast with those of a previous study7 in
which the controls showed the highest radiographic density.
Bone healing was evaluated radiographically using a fixed
time interval. Small but significant differences were found
only for the occurrence of the periosteal reactions and callus
formation, but not for radiographic density and soft tissue
reactions. This was also in contrast with the previous study,
where more radiographic findings were significantly pres-
ent.7 A possible explanation for the differences between each
study might be that in the present study, the radiographic
evaluation was done over a 12-week period after surgery
compared to a 32-week follow-up in the previous study.
Major differences between composites were seen from 8-week
postsurgery in both studies. Not surprisingly, standard ra-
diographic techniques had a low sensitivity to detect signifi-
cant changes in the early phases of bone healing.
Von Kossa–positive material is indicative for the presence
of phosphate and carbonate, the anions that bind calcium in
tissues. On the bone sections in the present study, the von
Kossa–positive material corresponded with the presence of
either the mineralized bone or the a-TCP particles that were
included in composite no. 3 (Fig. 5). On the other hand, von
Kossa–negative staining mainly refers to the presence of pure
fibrous tissue, whereas colorless zones are indicative for the
presence of the pure polymer or possible artefacts.
Overall, the empty control defects healed very fast. The
results of the present study demonstrated insufficient os-
teoconductive properties of the used composites that were
characterized by the presence of fibrous tissue surrounding
the implant material. This was in contrast with the results of
the previous study,7 where bone ingrowth at the periphery
of the composite material was seen even at early stages. A
possible explanation for this lack of bone ingrowth in the
present study might be the lower porosity of the polymer
compared to the previous study because no porogen was
used in the present study as the addition of gelatine as a
porogen seemed to have a negative influence on in vitro cell
viability.8 The present study identified several tissue clusters
in the composites originating from the seeded BMSCs as
tissue clusters were absent in the polymer composite without
BMSCs. This underlines the cells’ potential to proliferate and
further differentiate in an osteogenic direction. Survival and
proliferation of the cells are only possible when the polymer
has an adequate porosity. No extra porogen was included in
the composition of the scaffolds. Preceding experiments
showed that porosity could be induced by the leaching of the
plastizer and as a result of the degradation of the polyester
and the CultiSpher microcarrier particles. Further, during
the mixing of the viscous crosslinkable polyester and the
cell-seeded microcarriers, air bubbles were trapped and
contributed as macroporous pockets. Preceding in vitro ex-
periments with cells grown on microcarriers and im-
mobilized in the crosslinkable polyester proved to maintain
an acceptable viability. Further, triacetin has a very low
molecular weight and is washed out fast, generating some
more micropores. The observed degree of proliferation of the
BMSCs was considered rather limited. A higher porosity of
the polymers would most likely have allowed a more pro-
nounced proliferation activity. It was surprising to observe
that a-TCP–supplemented polymers demonstrated less
BMSC proliferation characterized by less amounts of tissue
and cells found around the microcarriers. Although a-TCP is
most likely not toxic for the cells, this calcium phosphate has
been reported to be inferior with regard to seeding efficacy,
increase in osteogenic marker genes, and three-dimensional
cell alignment compared to other bone grafts like mineral-
ized collagen.32 The addition of a-TCP might also decrease
the overall porosity of the polymer, thus possibly interfering
with proliferation potential.
The presence of clusters of cells around the composites in a
single goat might be indicative for the occurrence of an in-
flammatory response because a small number of these cells
were identified as T-lymphocytes. This might have been in-
duced by the presence of the slowly degrading polymers,
although no adverse reactions were recorded in previous
studies7,8 and no clinical signs of inflammatory reactions
(lameness; swelling, redness, and hyperthermia at the oper-
ated legs) were observed during the study period in the other
goats. A more obvious explanation might be that these
findings represented a reaction against a possible contami-
nation during surgery.
Histomorphometrical evaluation confirmed a slower
bone healing and remodeling in bone defects containing
composites in comparison with control defects, although no
differences were found between the three composites. The
absence of ingrowth of new bone into the polymer com-
posites reflects the limited osteoconductive properties of the
polymers.
Similar to the previous study in goats without the addition
of BMSCs,7 polymer degradation failed to become visible
during the first 12 weeks postsurgery. The present study ac-
centuates the need for further physicochemical adaptations of
the polymers used to improve their osteoconductive proper-
ties. More recently, hydrogels seeded with bone-forming cells
have been reported as promising alternative scaffolds for
bone regeneration purposes.3,12,33–40 These substances can
also be crosslinked by photopolymerization.41,42
The BMSCs in the present study have been cultivated in
an osteogenic medium to stimulate their differentiation to
bone-forming cells. A clearly bone-forming potential was
encountered in the composite-seeded cells (Fig. 12), proving
the osteogenic capacity of the BMSCs in the used polymer.
In a previous study,11 metachromatic staining was also
observed, which was suggestive for the presence of mature
bone. Most likely, all calcified tissues will have a metachro-
matic staining after immunohistochemical staining with the
techniques of the present protocol. The metachromatic
granular material in composite no. 3 was identified as a-TCP
particles using the standard light microscopic techniques.
The second part of our research hypothesis, in which we
anticipated an improvement in bone healing characteristics
of the treated cortical defects compared to earlier reported
results,7 is not true due to a too low resorption and porosity
of the polymers impeding BMSCs’ proliferation and bone
ingrowth.
Conclusion
The use of osteogenic differentiated BMSCs is promising
in the process of bone tissue engineering and has been re-
ported in different animal models.12–21 Despite their excel-
lent biocompatibility, the osteoconductive characteristics of
the in situ crosslinkable methacrylate-endcapped poly-(D,
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L-lactide-co-e-caprolactone) combined with BMSCs were
limited in the first weeks after implantation. The addition of
a-TCP seemed to have a less positive effect on expansion and
growth of the BMSCs than other polymer composites. A
faster resorption and higher porosity of the polymer seems
imperative to promote BMSCs’ proliferation and encourage
bone ingrowth from the surrounding tissues. Further bio-
chemical adaptation of the present polymer is mandatory to
improve its bone grafting properties. Their in situ cross-
linkable characteristic in combination with osteogenic dif-
ferentiated BMSCs offers potentials for the restoration of
complex orthopedic situations.
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